Arizona’s Drug Supply Is Turning Into a Guessing Game. Washington Just Took Away the Answer Key.

In 2025, Baltimore’s Penn North neighborhood lived through three mass-overdose events — people collapsing within minutes of each other on the same blocks, one episode serious enough to send more than twenty people to the hospital at once, according to NPR’s August 2026 reporting. Nobody in that crowd knew what they’d actually bought. That’s what an unpredictable, adulterated opioid supply looks like from ground level: not one bad batch, but a supply so inconsistent entire blocks go down together.

Baltimore’s harm reduction workers responded the way they always have — by testing the drugs before people used them. The Baltimore Harm Reduction Coalition expanded its fentanyl and benzodiazepine test strip services in response. Now, per NPR, the federal Substance Abuse and Mental Health Services Administration (SAMHSA) has barred grantees from spending that money on test strips, syringes, or overdose hotlines — funds it wants redirected to naloxone alone. Baltimore must cut wound care and hygiene kits just to self-fund strips, even as the city’s 40%-plus decline in overdose deaths since 2023 is a gain those same workers now fear is at risk.

Cutting the tools that tell people what they’re about to use, at the exact moment the drug supply is becoming harder to predict and harder to reverse, is not a neutral budget decision — it is a policy choice that will get people killed who would otherwise have lived.

That contradiction is playing out nationally, and with particular force in Arizona, where the supply itself is mutating in three directions at once: powdered fentanyl replacing pills, a class of opioids that ordinary naloxone doses often can’t touch, and a scheduling crackdown on one dangerous adulterant feeding demand for a worse one.

Arizona’s Fentanyl Supply Went From Predictable to Unrecognizable

For years, Arizona’s fentanyl problem had a recognizable shape: counterfeit pills, pressed to look like oxycodone or Xanax, sold on the assumption — often wrong, but at least consistent — that each pill carried roughly the same dose. That shape is gone. Over the last two years, powdered fentanyl has largely replaced counterfeit pills in Arizona’s illicit market, according to Axios Phoenix. Powder is cheaper to produce and easier to cut, but its potency swings far more widely from batch to batch than a pressed pill — the same visual dose can be survivable or lethal, with no way to tell by looking.

The mortality data confirms it. Arizona’s overdose death rate hit an all-time high of 43.5 per 100,000 people, now exceeding West Virginia’s long-standing grim benchmark, putting Arizona and New Mexico ahead of every other state in the lower 48, per Axios and AZFamily. Arizona’s overdose deaths rose from 2,531 in 2024 to 2,988 in 2025 — a 17-to-18% increase — while national overdose deaths fell roughly 14% over the same period. Narrow the lens to synthetic opioids and it gets starker: Arizona’s synthetic-opioid deaths rose about 33% in the twelve months ending September 2025, even as national fentanyl deaths fell about 31%. Whatever is driving the national improvement, Arizona is moving the opposite way — a pattern Rize’s Arizona Watch coverage keeps tracking.

Nitazenes Are the Opioids Naloxone Wasn’t Built to Handle Alone

Layer a second problem on top of the powder shift: nitazenes, a class of synthetic opioids developed decades ago as analgesics and never approved for medical use, are now spreading through the same illicit supply that carries fentanyl. According to STAT News, some nitazene compounds are up to 40 times more potent than fentanyl and roughly 500 times more potent than morphine. They’ve been confirmed in 48 of 50 states — no longer a regional curiosity, but most of the country. Ohio alone accounts for more than a third of the nation’s positive lab reports, but the class has spread far past any single state’s borders, part of what makes it relevant to Arizona’s opioid landscape even before local case counts catch up.

The naloxone problem should worry every case manager and every person carrying a rescue kit. A standard dose is calibrated to outcompete the opioid typically present in a fentanyl-driven overdose. Nitazenes, being far more potent, occupy those receptors more aggressively and for longer, so one dose frequently isn’t enough. STAT found naloxone was given in only one in three nitazene-involved overdose deaths in the first place — most people who died never got the chance for even one dose, let alone the multiple doses these compounds often require. The CDC’s overdose surveillance system has confirmed more than 1,100 nitazene deaths, with researchers estimating roughly 2,000 since 2019; confirmed cases climbed from 27 in 2020 to 409 in 2024, and 747 deaths were confirmed across 2023 and 2024 combined. That is not a plateau. That is a curve still climbing.

A standard dose is calibrated to outcompete the opioid typically present in a fentanyl-driven overdose.

The Xylazine Scheduling Experiment Backfired, and History Predicted It

The third thread is the most quietly alarming, because it shows what happens when supply-side drug policy succeeds narrowly and fails broadly. Several states moved to schedule xylazine — the veterinary sedative known on the street as “tranq,” which resists naloxone entirely and causes its own severe, treatment-resistant wounds — to choke off supply. A new analysis, described by Healio and posted as a preprint on medRxiv by researchers Zhu and Oh (not yet peer-reviewed, treat the numbers as preliminary), examined the National Forensic Laboratory Information System — NFLIS, the government’s database of what drugs turn up when crime labs test seized samples — across 14 states from 1999 to 2025. An adulterant, in plain terms, is any substance mixed into a drug supply that the buyer didn’t ask for and usually doesn’t know is there.

The finding: xylazine scheduling was not associated with any decline in xylazine detections. It was associated with a sharp rise in medetomidine — a related but even stronger veterinary sedative — appearing instead. The researchers used a quasi-experimental design, comparing states before and after they scheduled xylazine against states that hadn’t yet, approximating the controlled comparison a lab experiment offers when you can’t randomize which states pass which laws. Out of 101,987 xylazine reports and 12,085 medetomidine reports, scheduling was associated with roughly 1,536.5 additional medetomidine detections per 100,000 drug samples (95% CI 211.1–2,861.9) — a wide range, but one direction.

This is the balloon effect: squeeze a drug supply in one place and it bulges out somewhere else, often somewhere worse, rather than disappearing. It’s close to the same mechanism that helped produce the fentanyl crisis in the first place — as heroin supply chains came under sustained enforcement pressure, traffickers had every incentive to substitute a synthetic opioid that was cheaper to produce, easier to smuggle, and far more potent per dose. Fentanyl won that market not because anyone wanted it specifically, but because it was the substitute that survived the pressure. Medetomidine appears to be following the identical logic one rung down the adulterant ladder.

Defunding the Tools to Read an Unreadable Supply

Put these threads together — inconsistent powder replacing predictable pills, an opioid class that routinely defeats a single dose of naloxone, and a scheduling policy manufacturing a more dangerous adulterant — and you get a supply less knowable than it’s been in years, at the exact moment SAMHSA is barring grantees from funding the test strips that let people find out what they’re about to use. Dr. Rebecca Sunenshine, medical director of the ASU Health Observatory, told KJZZ that Arizona’s crisis is tangled up with homelessness, housing instability, and border proximity driving up fentanyl’s potency — and that the response has to include expanded treatment access alongside naloxone and test-strip availability, not naloxone alone. She was describing the same tradeoff SAMHSA’s rule just made in reverse. Her data also complicates the easy story about Arizona’s heat deaths: they skew roughly 80% methamphetamine, since meth impairs the body’s ability to regulate temperature, with just under half involving opioids — 65% of the 40 confirmed Maricopa County heat deaths this summer involved substances, per follow-up AZFamily reporting. The opioid supply and the heat crisis are tangled together, not separate emergencies.

If you’re testing what you have before you use it, know that the tools to do that are exactly what’s being defunded right now — true in Baltimore, true in Phoenix. The Baltimore Harm Reduction Coalition is having to strip out wound care just to keep test strips on the table — a trade nobody should have to make, and one that exists only because federal money that used to cover both got redirected by policy, not by need.

None of this changes what still works. Naloxone remains legal, remains available over the counter at Arizona pharmacies, and remains yours to carry — that has not been taken away, and multiple doses on hand matter more now than a year ago given how nitazenes behave. What’s disappearing isn’t the rescue drug. It’s the information that would tell you, before the moment you need it, what you’re actually up against.

It’s the information that would tell you, before the moment you need it, what you’re actually up against.